Pentazocine/Paracetamol

Pentazocine/Paracetamol

Discontinued

DEA Class;  Discontinued

Common Brand Names; Talacen

  • Analgesics, Opioid Combos; 
  • Analgesics, Opioid Partial Agonist

Pentazocine: Opioid agonist; inhibits ascending pain pathways, which causes alteration in response to pain; produces analgesia, respiratory depression, and sedation

Acetaminophen: Nonopiate, nonsalicylate analgesic: may work peripherally to block pain impulse generation; acts on hypothalamus to produce antipyresis

Hypersensitivity

Hepatitis or severe hepatic/renal impairment

Toxin-mediated diarrhea

Pseudomembranous enterocolitis

Respiratory depression

Pentazocine

  • Circulatory depression, increased blood pressure, shock, tachycardia

  • Apprehension, confusion and hallucinations (especially in elderly), depression, disturbed dreams, dizziness, euphoria, floating feeling, headache, insomnia lightheadedness, nervousness, sedation, syncope, weakness or faintness

  • Diaphoresis, flushed skin (including plethora), rash, pruritus, urticaria, edema of the face

  • Abdominal distress, anorexia, constipation, cramps, diarrhea, nausea, vomiting

  • Depression of leukocytes (especially granulocytes), moderate transient eosinophilia

  • Cutaneous depression, stinging, soft tissue induration, nodules, , ulceration, severe sclerosis of the skin

  • Blurred vision, focusing difficulty, nystagmus, diplopia, miosis

Acetaminophen

  • Laryngeal edema

  • Angioedema

  • Pruritic maculopapular, rash, urticaria

  • Agranulocytosis, leukopenia, neutropenia, pancytopenia, thrombocytopenia, thrombocytopenic purpura

  • Hepatotoxicity

  • Anaphylactoid reaction

May cause physical and psychological dependence

Acetaminophen associated with cases of acute liver failure, at times resulting in liver transplant and death; risk increases in individuals with underlying liver disease, alcohol ingestion, and/or use of more than 1 acetaminophen-containing product (see Black Box Warnings)

Acetaminophen: Risk for rare, but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash

G6PD deficiency

Acute asthma

Bradycardia

Chronic respiratory disease, cardiac conduction disorder

Head injury, intracranial hypertension

Inflammatory bowel disease, acute abdominal pain

Benign prostatic hypertrophy

Biliary spasm

Liver disease

Drug dependence, substance abuse

Epilepsy

Gallbladder disease

Hypotension

Hypothyroidism

Mood changes

Urinary system procedure

Renal disease

Urethral stricture

Pregnancy category: (pentazocine) C; D if used for prolonged periods or near term

Lactation: Unknown if excreted in breast milk, use caution

Adults

1 tablet PO q4hr; not to exceed 6 tablets/day

Pediatric

Dose determined by pain severity and patient response

<12 years: Safety & efficacy not established

12 years or older: 1 tablet PO q4hr; not to exceed 6 tablets/day

FDA is asking manufacturers to limit acetaminophen in prescription products to 325 mg/dosage unit; manufacturers have until January 14, 2014 to comply

pentazocine/acetaminophen

tablet: Schedule IV

  • 25mg/650mg
DrugsAce
Logo